NR1H4 and Hepatic fibrosis: Studies have shown that the FXR agonist Obecholic Acid can reduce liver inflammation and fibrosis in TAA-induced toxic cirrhosis, and even reverse hepatic fibrosis (Anfuso et al., 2020).